Abstract:Authors' reply Sir—We disagree with C J Hawkey and colleagues that elderly patients with comorbid conditions do not warrant prophylactic treatment. These patients are at increased risk of developing gastrointestinal complications induced by the use of non-steroidal anti-inflammatory drugs (NSAIDs).1Silverstein FE Graham DY Senior JR et al.Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomised, double-blind, placebo-controlled trial.Ann Intern Med. 1995; 123: 241-249Crossref PubMed Scopus (1108) Google Scholar Moreover, patients without previous exposure to NSAIDs are also at risk, particularly during the first few weeks of NSAID therapy.2Langman MJS Weil J Wainwright P et al.Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.Lancet. 1994; 343: 1075-1078Summary PubMed Scopus (843) Google Scholar Although little could be done for this group of patients in the past, our proposal to eradicate Helicobacter pylori in these patients is a quick and cheap primary preventive treatment, unlike the long-term use of acid-suppression drugs. Certainly, the issue of interaction between H pylori and NSAIDs in the pathogenesis of peptic ulcers is far from settled. Hawkey and co-workers make the interesting observation that acid-suppressive-maintenance treatment is more effective in individuals infected with H pylori than in those not infected. However, the primary aim of their study was to compare the protective effects of two acid-suppressive agents against NSAID-induced injury, instead of the role of H pylori infection. Furthermore, the same group of investigators have also reported a synergistic effect between H pylori and aspirin in the development of bleeding peptic ulcers.3Hawkey GM Stack WA Pearson G Everitt S Logan RFA Hawkey CJ Nonsteroidal anti-inflammatory drugs, aspirin and Helicobacter pylori as risk factors for bleeding ulcers.Gut. 1997; 29: A5Google Scholar We suspect that the interaction between H pylori and NSAIDs may not be a simple all-or-none relation. Such factors as history of ulcer disease, gastric or duodenal ulcer, and bleeding or non-bleeding ulcers may all affect the outcome of the patients. A simple 1-week course of antimicrobial therapy would be a pragmatic and cost-effective way to reduce the risk of gastrointestinal complications. O M P Jolobe notes the confounding effect of spontaneous healing, but spontaneous ulcer healing with long-term NSAID therapy would have had little influence on the outcome of our study because of the large difference in the rate of peptic ulcers between H pylori-positive (26%) and H pylori-negative (3%) patients. The rate of ulcers in the H pylori-positive group agreed with that reported by Ekstrom and colleagues'4Ekstrom P Carling L Wetterhus S et al.Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study.Scand J Gastroenterol. 1996; 31: 753-758Crossref PubMed Scopus (256) Google Scholar long-term study, which showed that the lesions observed were not simply a transient response to acute mucosal injury. Most of our patients were older than 60 years and, thus, were more susceptible to NSAID-related injury. The age distribution may also explain why studies based on young, healthy volunteers do not show any positive interaction between use of NSAIDs and H pylori.5Thillainayagam AV Tabaqchali S Warrington SJ Farthing MJG Interrelationships between Helicobacter pylori infection, non-steroidal anti-inflammatory drugs and gastroduodenal disease: a prospective study in healthy volunteers.Dig Dis Sci. 1994; 39: 1085-1089Crossref PubMed Scopus (61) Google Scholar However, since the mean age of our two treatment groups were similar, age-related risk cannot account for the remarkable between-group difference in the rate of gastric and duodenal ulcers. Helicobacter pylori, NSAIDs, and peptic ulcersFrancis Chan and colleagues (Oct 4, p 975)1 suggest that eradication of Helicobacter pylori may prevent peptic ulcers caused by the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The patients Chan and co-workers investigated would not usually be considered for preventative treatment since they were excluded from the study if they had had previous exposure to NSAIDs, a history of peptic ulcer disease, or an ulcer at the baseline endoscopy. These exclusion criteria may explain why individuals who did not have H pylori did so well in the study compared with previous studies in which H pylori has had little or no effect on the risk of developing ulcers or ulcer complications. Full-Text PDF Helicobacter pylori, NSAIDs, and peptic ulcersIn the study by Francis Chan and colleagues,1 the 8 weeks' duration of naproxen therapy may have been too short to allow for the confounding effect of spontaneous healing, as reported by Davis and co-workers2 in six of 13 patients who continued to take non-steroidal anti-inflammatory drugs (NSAIDs) in the placebo group of a trial evaluating cimetidine over a 6-week period. Another important confounding variable is the age-related nature of susceptibility to NSAID-related gastropathy3—probably due to the age-related decline in gastroduodenal prostaglandin content. Full-Text PDF

Nonsteroidal Anti-inflammatory Drug Use Is a Significant Cause of Peptic Ulcer Disease in a Tertiary Hospital in Singapore: A Prospective Study

Upper gastrointestinal disorders induced by non-steroidal anti-inflammatory drugs

Helicobacter Pylori and Nonsteroidal Anti-Inflammatory Drugs

The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study.

Is Non-Helicobacter Pylori, Non-Nsaid Peptic Ulcer a Common Cause of Upper GI Bleeding? A Prospective Study of 977 Patients

Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection

Does Eradication of Helicobacter Pylori Impair Healing of Nonsteroidal Anti-Inflammatory Drug Associated Bleeding Peptic Ulcers? A Prospective Randomized Study.

Helicobacter pylori infection and peptic ulcers

Helicobacter Pylori, NSAIDs, and Peptic Ulcers

A Survey of Nonsteroidal Anti-Inflammatory Drugs and Aspirin Associated Peptic Ulcer Bleeding in Hospitals

NSAID-induced Gastric Ulcer Disease: A Deleterious Connection

114 Combination of a Cyclooxygenase (COX)-2 Selective NSAID and a Proton Pump Inhibitor for Prevention of Gastroduodenal Ulcers in Very High Risk Patients: A One-Year, Double-Blind, Randomized Trial

Poor Awareness of Preventing Aspirin-Induced Gastrointestinal Injury with Combined Protective Medications

Nonsteroidal anti-inflammatory drug (NSAID) prescribing after gastrojejunostomy: A preventable cause of morbidity

Racial differences in Helicobacter pylori seroprevalence in Singapore: correlation with differences in peptic ulcer frequency

A Questionnaire-Based Survey on the Prescription of Non-Steroidal Anti-Inflammatory Drugs by Physicians in East Asian Countries in 2007

Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment

Status and influence factors of helicobacter pylori infection in patients taking non-steroidal antiinflammatory drugs in Beijing

Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial

S2294 Evaluating Prophylactic Gastric Acid Suppression and Risk Factors for Gastrointestinal Adverse Effects in Chronic NSAID Users: A Retrospective Analysis

Similar Efficacy of Proton-Pump Inhibitors Vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin